- Study Protocol
Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
- Dured Dardari,
- Claire Thomas,
- Francois-Xavier Laborne,
- Caroline Tourte,
- Elodie Henry,
- Megane Erblang,
- Stéphanie Bourdon,
- Alfred Penfornis and
- Philippe Lopes
The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factor...